Related Experiment Videos
Immunosuppression as initial treatment for gold induced aplastic anemia
M J Mant1, A S Russell, J S Percy
1Department of Medicine, University of Alberta Hospital, Edmonton, Canada.
The Journal of Rheumatology
|October 1, 1987
Summary
Antithymocyte globulin therapy shows promise for treating severe aplastic anemia caused by gold. This treatment led to significant improvement in 8 out of 12 patients, suggesting it may be an optimal initial therapy.
Area of Science:
- Hematology
- Immunology
- Toxicology
Background:
- Gold therapy can induce severe aplastic anemia, a life-threatening condition.
- Treatment options for gold-induced aplastic anemia are limited, with variable success rates.
Observation:
- Three patients with severe aplastic anemia secondary to gold exposure were treated with antithymocyte globulin (ATG).
- Two patients achieved hematologic recovery with normal blood counts and platelet levels exceeding 100 x 10(9)/L over two years post-treatment.
- One patient refractory to ATG and cyclosporine successfully engrafted after allogeneic bone marrow transplantation.
Findings:
- ATG therapy resulted in significant hematologic improvement in 8 of 12 reported cases of gold-induced aplastic anemia.
- The overall response rate for ATG in this cohort surpasses that of previously reported treatments.
- Concurrent improvement in gold-associated arthritis was noted in all three treated patients post-aplasia recovery.
Implications:
- Antithymocyte globulin (ATG) represents a potentially optimal first-line treatment for severe aplastic anemia induced by gold.
- Further research is warranted to confirm ATG's efficacy and safety profile in this specific patient population.
- Understanding the immunopathogenesis of gold-induced aplastic anemia may guide future therapeutic strategies.